The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Sheila A. Doggrell

Division of Health Practice

Auckland University of Technology--Akoranga Campus

Northcote

Auckland

New Zealand

[email]@xtra.co.nz

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Health Practice, Auckland University of Technology--Akoranga Campus, Northcote, Auckland, New Zealand. 2005 - 2006
  • The University of Queensland, School of Biomedical Sciences, QLD 4072, Australia. 2005

References

  1. Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation. Doggrell, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  2. Nitrone spin on cerebral ischemia. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006) [Pubmed]
  3. Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease. Doggrell, S.A. Expert. Opin. Investig. Drugs (2006) [Pubmed]
  4. Ceramide as a target in emphysema. Doggrell, S.A. Expert Opin. Ther. Targets (2006) [Pubmed]
  5. Bradykinin B2 receptors as a target in diabetic nephropathy. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006) [Pubmed]
  6. New targets in and potential treatments for cholesterol gallstone disease. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006) [Pubmed]
  7. Conivaptan Yamanouchi. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005) [Pubmed]
  8. Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  9. Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  10. Rho-kinase inhibitors show promise in pulmonary hypertension. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  11. Ximelagatran--recent comparisons with warfarin. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  12. Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005) [Pubmed]
  13. Taking the 20-HETE out of the cardiovascular system: the potential of 20-HETE synthesis inhibitors. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005) [Pubmed]
  14. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  15. More support for high-dose atorvastatin in coronary artery disease. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  16. Pregabalin or morphine and gabapentin for neuropathic pain. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  17. Potential of growth hormone-releasing hormone antagonists (JV-1-36 and JV-1-42) for the treatment of brain tumours. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  18. Recent findings with docetaxel in postoperative treatment for breast cancer. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  19. Inflammation, the key to much pathology. Doggrell, S.A. Drug News Perspect. (2005) [Pubmed]
  20. Highlights from the First International Conference in Vascular Medicine, held August 26-28, 2005, in Melbourne, Australia. Vascular medicine in Australia and Germany. Doggrell, S.A. Drug News Perspect. (2005) [Pubmed]
  21. Urotensin-II and the cardiovascular system--the importance of developing modulators. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  22. Efalizumab for psoriasis?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  23. The endothelin system and its role in acute myocardial infarction. Doggrell, S.A. Expert Opin. Ther. Targets (2004) [Pubmed]
  24. Vascular biology support for the use of bevacizumab in colorectal cancer. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  25. Sarpogrelate: cardiovascular and renal clinical potential. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  26. Intrathecal ziconotide for refractory pain. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  27. Is RGS-2 a new drug development target in cardiovascular disease?. Doggrell, S.A. Expert Opin. Ther. Targets (2004) [Pubmed]
  28. Dawn of Aurora kinase inhibitors as anticancer drugs. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  29. Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents. Doggrell, S.A. Expert. Rev. Cardiovasc. Ther (2004) [Pubmed]
  30. Tolvaptan (Otsuka). Doggrell, S.A. Curr. Opin. Investig. Drugs (2004) [Pubmed]
  31. ETC-588 (Pfizer). Doggrell, S.A. Curr. Opin. Investig. Drugs (2004) [Pubmed]
 
WikiGenes - Universities